Michel Goldman (born 1 January 1955) is a Belgian medical doctor who specialized in internal medicine and immunology.
Michel Goldman graduated as a Medical Doctor (1978) from Université Libre de Bruxelles (ULB), Belgium, and received his PhD in medical sciences (1981) from Université de Genève, Switzerland. He is board certified in internal medicine (1984) and clinical biology (1993).
From 1990 to 2008, he heads of the Department of Immunology-Hematology-Transfusion at Erasme Hospital in Brussels, and from 2004 to 2009 serves as the first Director of the Institute for Medical Immunology built on the Charleroi campus of ULB, with the support of GSKBiologicals and the Walloon Region.
In 2009, Michel Goldman becomes the first Executive Director of the Innovative Medicines Initiative (IMI) a joint undertaking between the European Commission and the European Federation of Pharmaceutical Industries and Associations. Managing a budget of €2 billion, he has been responsible for the launch of 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer's dementia, cancer, diabetes, immuno-inflammatory disorders, autism, chronic pulmonary diseases and drug safety.
Michel Goldman is Professor of Immunology and Pharmacotherapy at ULB. He is a member of the Board of Directors of CQDM (Canadian consortium for precompetitive research) , of the Board of the Tuberculosis Vaccine Initiative and of the Strategic and Scientific Advisory Board of GenomeQuebec. He also serves as chairman of the Scientific Committee of Effimune S.A., a French biotechnology company.
Starting from September 2015, Michel Goldman is leading the Institute for Interdisciplinary Innovation in Healthcare (I3h), a ULB centre that has the mission of fostering research, education and outreach networks for the benefit of patients and other stakeholders.
In January 2016 Michel Goldman has been appointed as the Field Chief Editor of Frontiers Medicine.
Awards and recognition
1992: Medical Prize Lucien Steinberg (shared with Pr. Peter Piot)
1999: Francqui Chair at the University of Namur
2000: Quinquiennal Prize of the Belgian National Fund for Scientific Research for Clinical Sciences
2001: Spinoza Chair at the University of Amsterdam
2003: Francqui Chair at the University of Liège
2006: Highly Cited Scientist recognition by the Thomson Institute for Scientific Information
2007: Doctor Honoris Causa degree of the University of Lille 2
Goldman, M; Rose, LM; Hochmann, A; Lambert, PH (1982). "Deposition of idiotype-anti-idiotype immune complexes in renal glomeruli after polyclonal B cell activation". Journal of Experimental Medicine. 155: 1385–1399. doi:10.1084/jem.155.5.1385.
Cogan, E; Schandené, L; Crusiaux, A; Cochaux, P; Velu, T; Goldman, M (1994). "Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome". New England Journal of Medicine. 330: 535–538. PMID 8302319. doi:10.1056/nejm199402243300804.
Marchant, A.; Devière, J; Byl, B; De Groot, D; Vincent, JL; Goldman, M. (1994). "Interleukin-10 production during septicaemia". Lancet. 343: 707–708. doi:10.1016/s0140-6736(94)91584-9.
Tassignon, J; Ismaili, J; Le Moine, A; Van Laethem, F; Leo, O; Vandevelde, M; Goldman, M (1999). "Azodicarbonamide inhibits T cell responses in vitro and in vivo". Nature Medicine. 5: 947–950. doi:10.1038/11392.
Goldman, M; Le Moine, A; Braun, M; Flamand, V; Abramowicz, D (2001). "A role for eosinophils in transplant rejection". Trends in Immunology. 22: 247–251. doi:10.1016/s1471-4906(01)01893-2.
Le Moine, A; Goldman, M (2003). "Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction ?". American Journal of Transplantation. 3: 101–106. doi:10.1034/j.1600-6143.2002.00026.x.
Wraith, D; Goldman, M; Lambert, PH (2003). "Vaccines and autoimmunity: what is the evidence ?". Lancet. 362: 1659–1666. doi:10.1016/s0140-6736(03)14802-7.
Goriely, S; Van Lint, C; Dadkah, R; Libin, M; De Wit, D; Demonte, D; Willems, F; Goldman, M (2004). "A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells". Journal of Experimental Medicine. 199: 1011–1016. PMC 2211877 . PMID 15051764. doi:10.1084/jem.20031272.
Goriely, S; Neurath, MF; Goldman, M (2008). "How microorganisms tip the balance between interleukin-12 family members". Nature Reviews Immunology. 8: 82–86. doi:10.1038/nri2225.
Garçon, N; Goldman, M (2009). "Boosting vaccine power". Scientific American. 301: 72–79. doi:10.1038/scientificamerican1009-72.
Research and innovation policy
Goldman, M (2012). "Public-private partnerships need honest brokering". Nature Medicine. 18: 341. PMID 22395691. doi:10.1038/nm0312-341.
Goldman, M (2013). "New frontiers for collaborative research". Science Translational Medicine. 5: 216.
Goldman, M; Seigneuret, N; Eichler, H.-G. (2014). "The Innovative Medicines Initiative: An engine for regulatory science". Nature Reviews Drug Discovery. 14: 1–2. PMID 25503331. doi:10.1038/nrd4520.
Murphy, D; Goldman, M; Loth, E; Spooren, W (2014). "Public-private partnership: a new engine for translational research in neurosciences". Neuron. 84: 533–536. PMID 25442930. doi:10.1016/j.neuron.2014.10.006.
Joanette, Y; Hirsch, E; Goldman (2014). "The global fight against dementia". Science Translational Medicine. 6: 267.
Lim, MD; Brumfield, MA; Goldman, M (2015). "Philanthropies as partners for drug development in public-private partnerships". Journal of Medicines Development Sciences. 1. doi:10.18063/JMDS.2015.01.002.
Gunn, M; Lim, M; Cross, D; Goldman, M (2015). "Public-private partnership for health innovation: time to assess research performance". Nature Biotechnology. 33: 811–812. doi:10.1038/nbt.3305.
